title: Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. TriVeneto Viral Hepatitis Group.
abstract: OBJECTIVE
  To define long-term outcome in patients with chronic hepatitis C who remain viremic after sustained biochemical response to interferon-alpha therapy.
  
  
  METHODS
  Prospective evaluation of an outpatient cohort.
  
  
  METHODS
  University hospital.
  
  
  METHODS
  107 patients with chronic hepatitis C who maintained normal aminotransferase levels as long as 12 months after interferon-alpha therapy. Patients were followed prospectively for an additional 6 to 36 months.
  
  
  METHODS
  Aminotransferase levels were monitored at 3-month intervals. Serum hepatitis C virus (HCV) RNA was tested by polymerase chain reaction before therapy, at the end of therapy, and 12 months after therapy. The HCV genotype was defined by spot hybridization using serum specimens obtained before treatment.
  
  
  RESULTS
  Hepatitis C virus RNA was detected in 27 (25%) patients with sustained biochemical response; 80 (75%) patients were negative for HCV RNA. Patients positive for HCV RNA were older (P < 0.001), had received a smaller interferon-alpha dose (P = 0.02), and were more frequently infected with HCV genotype 2 (P < 0.01). Liver histologic findings were active in 57% of patients positive for HCV RNA, despite normal alanine aminotransferase levels, compared with only 12% of patients who were negative for HCV RNA (P = 0.01). The estimated probability of hepatitis relapse by 4 years after therapy was 53% in viremic patients and 0% in patients negative for HCV RNA (P < 0.001).
  
  
  CONCLUSIONS
  Patients with chronic hepatitis C should be tested for serum HCV RNA 1 year after a sustained biochemical response to interferon-alpha therapy to determine whether the response is complete and permanent.
authors.affiliation: University of Padova, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Chemello
authors.forename: L
authors.initials: L
authors.lastname: Cavalletto
authors.forename: C
authors.initials: C
authors.lastname: Casarin
authors.forename: P
authors.initials: P
authors.lastname: Bonetti
authors.forename: E
authors.initials: E
authors.lastname: Bernardinello
authors.forename: P
authors.initials: P
authors.lastname: Pontisso
authors.forename: C
authors.initials: C
authors.lastname: Donada
authors.forename: F
authors.initials: F
authors.lastname: Belussi
authors.forename: S
authors.initials: S
authors.lastname: Martinelli
authors.forename: A
authors.initials: A
authors.lastname: Alberti
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000998:Antiviral Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D002908:Chronic Disease; D016174:Hepacivirus / Q000235:genetics; D006526:Hepatitis C / Q000201:enzymology / Q000628:therapy* / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008875:Middle Aged; D011446:Prospective Studies; D012367:RNA, Viral / Q000097:blood; D012008:Recurrence; D016896:Treatment Outcome; D014766:Viremia / Q000201:enzymology / Q000628:therapy*
chemical_list: D000998:Antiviral Agents; D015415:Biomarkers; D016898:Interferon-alpha; D012367:RNA, Viral; D000410:Alanine Transaminase